U6 small nuclear RNA 369, pseudogene (RNU6-369P)

RNU6-369P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA plays a key role in the catalytic mechanism of the spliceosome, a complex responsible for the removal of introns from pre-mRNA in eukaryotes[1][3]. However, pseudogenes like RNU6-369P are nonfunctional genomic sequences that resemble functional genes but typically lack the ability to be transcribed or translated due to loss of regulatory elements, accumulation of disruptions, or both[2][5]. Pseudogenes can arise either by gene duplication (unprocessed) or via retrotransposition (processed); RNU6-369P is classified as a processed pseudogene, lacking introns and not evolving under selective pressure[2][4]. As with most RNA pseudogenes, RNU6-369P is not transcribed into a functional product and has no established roles in normal physiology or disease, nor is it known to act as a therapeutic target or biomarker. Occasionally, pseudogenes can be transcribed as long non-coding RNAs with regulatory roles, but there is no evidence for such a function in RNU6-369P[4]. Additional notes: - There is nothing inherently "wrong" with the name in terms of nomenclature, but RNU6-369P is not a protein, receptor, or actionable target—so using it as a drug target or biomarker is incorrect. - Pseudogenes, by definition, are usually nonfunctional; their annotation in target databases may simply note their presence in the genome without implying any therapeutic relevance[2][4]. - Functional U6 snRNA genes are critical for splicing, but pseudogenes like RNU6-369P do not contribute directly to these processes[1][3]. In summary: RNU6-369P is a processed pseudogene derived from the U6 small nuclear RNA gene and is not a therapeutic target, functional RNA, or protein. It has no direct drug, biomarker, or disease associations, and no molecular function beyond being a nonfunctional genomic relic[2][3][4].

Other names

RNU6-369PRNA, U6 small nuclear 369, pseudogene